Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie is set to announce Q3 earnings, with expectations of $2.92 EPS and $14.28 billion in revenue ... 33.68% over the past year, 18.68% YTD. Let’s look at what the charts indicate for AbbVie ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Last year, pharmaceutical ... $1 billion less than AbbVie's acquisition of Cerevel. Still, the company survived the Rova-T ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items ... appreciation alone. However, AbbVie also paid dividends during these 10 years. AbbVie's dividend yield is currently ...

AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...

As of Q3 2024, Humira sales were $2.2 billion globally, but AbbVie's total revenue was $14.4 billion. Its immunology portfolio (which includes all three of the medicines) grew by 3.9% year over ...